May 4th, 2026

The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.

Company Guidance

The company provided robust commercial and pipeline guidance backed by many specific metrics: Q1 total revenue for the three marketed products was $191.2M (+57% YoY) driven by AUVELITY net product revenue of $153.2M (+59%), SUNOSI $33.9M (+34%, including $32.6M in net sales and $1.3M royalties) and SYMBRAVO $4.1M; AUVELITY and SUNOSI gross‑to‑net discounts were in the low‑to‑mid‑50s (expected to improve) while SYMBRAVO was in the high‑70s. Financials and runway: cost of revenue $14.7M, R&D $52.7M, SG&A $185M, net loss $64.5M ($1.26/sh) including $23.4M stock‑based comp, and cash of $305M (said to be sufficient to fund operations into cash‑flow positivity). Commercial posture and peak guidance: AUVELITY had >223,000 scripts in the quarter (+35% YoY), ~60,000 unique prescribers (5,500 new in Q1), 78% commercial/100% Medicare‑Medicaid coverage (86% total), an expanded sales force to ~630 reps targeting ~68,000 HCPs and updated peak sales potential of at least $8B (≈$4B per indication); SYMBRAVO had >17,000 scripts (+36% vs Q4), ~57% coverage with a new 17M‑lives contract and a rep force of ~150; SUNOSI had ~54,000 scripts (+16% YoY), >16,500 prescribers and ~83% coverage. Pipeline/regulatory guidance: a pipeline of 6 candidates targeting 10 indications, NDA submitted for AXS‑12 (narcolepsy/cataplexy; ~185,000 U.S. patients), multiple Phase III starts imminent (including solriamfetol ENGAGE topline H2 2026 and a shift‑work trial with topline 2027) and Phase‑III enabling work for AXS‑20 this year.